Animal study links gut repair to reversal of severe fatty liver disease
Researchers report that the experimental tripeptide DT-109 reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse and nonhuman-primate models. The compound reduced Clostridium perfringens, lowered intestinal ammonia, reinforced the gut barrier and was associated with less liver inflammation and MASH severity. The findings have not yet established safety or effectiveness in people.
The story
A Michigan Medicine-led research team reported that DT-109, an experimental glycine-based tripeptide, reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models. The researchers examined mice and nonhuman primates and focused on the gut–liver axis: the close relationship in which substances from the intestine can reach the liver through the bloodstream. Their experiments linked excess Clostridium perfringens in the intestine with ammonia production, damage to the intestinal lining and movement of microbial products into the body. Those products were associated with liver inflammation and activation of CD8+ T cells in MASH. According to the report, DT-109 reduced C. perfringens and intestinal ammonia, protected the intestinal epithelial barrier and limited the movement of pro-inflammatory microbial substances beyond the gut. In nonhuman primates, the treatment reduced liver inflammation and the severity of MASH. The paper, published in the Journal of Clinical Investigation, builds on the team's earlier animal work showing that DT-109 could improve MASH by offering a proposed mechanism for that effect. The compound remains experimental; the source says further evaluation is planned with the aim of advancing toward clinical trials.
Why it matters
MASH is a severe form of fatty liver disease in which fat accumulation, inflammation and cell damage can progress to cirrhosis, liver cancer or liver failure. The source estimates that it affects about 7% of the global population and says effective therapies remain limited. This research matters because it suggests that intestinal bacteria, ammonia and barrier integrity may be modifiable drivers of liver injury rather than merely accompanying features of the disease. That could guide the design and testing of treatments aimed at preventing inflammatory material from reaching the liver.
Evidence and context
The report places MASH within the gut–liver axis rather than treating the liver as an isolated organ. Under the mechanism described, ammonia produced by C. perfringens damages the intestinal barrier; microbial products can then enter circulation and contribute to liver inflammation. DT-109 was designed as a small tripeptide and, according to the researchers, acts primarily in the gastrointestinal tract while producing effects in the liver. The source also cites earlier animal findings that DT-109 reduced atherosclerotic plaque formation and prevented vascular calcification in nonhuman primates. Those results raise questions about whether barrier-focused treatment could affect related metabolic and cardiovascular processes, but they do not demonstrate benefits for patients or for conditions such as inflammatory bowel disease.
Limits and unknowns
The evidence is preclinical, not a human treatment result. Mouse and nonhuman-primate findings can help identify biological mechanisms, but they cannot establish the dose, safety, durability or clinical benefit of DT-109 in people with MASH. The report notes that researchers are aiming to move the compound toward clinical trials, without giving a trial start date or reporting human efficacy results. There is also a disclosed financial interest: the University of Michigan holds the patent and licensed DT-109 to Diapin Therapeutics; the university and researcher Y. Eugene Chen have ownership interests, and Diapin supplied the compound.
Follow the story
Share it, watch the explainer, or continue with the reporting trail.
Animal study links gut repair to reversal of severe fatty liver disease
A short visual explainer for readers who want the story in a different rhythm.
Highlights
- Early results in animals
- DT-109 tested in two animal models
- Changes in bacteria, ammonia and the gut barrier
- Less liver inflammation in primates
Transcript
An experimental peptide reversed MASH, a severe form of fatty liver disease, in animal models.
A Michigan Medicine-led team tested DT-109 in mice and nonhuman primates, tracking gut-liver changes.
DT-109 reduced Clostridium perfringens, lowered intestinal ammonia, and reinforced the gut barrier in animals.
For people with MASH, primates' reduced liver inflammation and disease severity suggest a possible benefit.
Human safety and effectiveness remain unknown; researchers plan further evaluation before moving toward clinical trials.